Suppression of the Nonsense Mutation in Homozygous Beta 0 Thalassaemia
Authors
Affiliations
The common form of beta thalassaemia associated with elevated haemoglobin A2 levels can be broadly classified as beta + or beta 0 type according to the presence or absence of beta-globin chain synthesis in the homozygous state. The molecular pathology of each type is heterogeneous. Apart from a subgroup of Indo-Pakistani patients, the beta-globin structural gene is intact in the majority of patients with beta 0 thalassaemia. The amount of beta-globin mRNA present in the reticulocytes of these patients varies: in some it is absent or barely detectable; in others, a substantial amount is present, but it is nonfunctional. We recently demonstrated that the molecular lesion in a Chinese patient with nonfunctional beta-globin mRNA was due to the mutation of the normal lysine codon AAG at amino acid 17 to the amber terminator codon UAG, which prematurely terminates the beta-globin chain. In the present study we demonstrate the first example of a nonsense mutation in humans which can be suppressed in vitro by the suppressor tRNA, as has been found in other eukaryotic cells and viruses.
Nuccetelli V, Mghezzi-Habellah M, Deymier S, Roisin A, Gerard-Baraggia F, Rocchi C Nucleic Acids Res. 2025; 53(2).
PMID: 39831305 PMC: 11744187. DOI: 10.1093/nar/gkaf010.
TDP1 splice-site mutation causes HAP1 cell hypersensitivity to topoisomerase I inhibition.
Goh C, Bader A, Tran T, Belotserkovskaya R, DAlessandro G, Jackson S Nucleic Acids Res. 2024; 53(2.
PMID: 39660638 PMC: 11754736. DOI: 10.1093/nar/gkae1163.
Awawdeh A, Tapia A, Alshawi S, Dawodu O, Gaier S, Specht C Nucleic Acids Res. 2024; 52(22):14244-14259.
PMID: 39558163 PMC: 11662663. DOI: 10.1093/nar/gkae1048.
Splicing the Difference: Harnessing the Complexity of the Transcriptome in Hematopoiesis.
Maul-Newby H, Halene S Exp Hematol. 2024; 140():104655.
PMID: 39393608 PMC: 11732257. DOI: 10.1016/j.exphem.2024.104655.
Therapeutic Nonsense Suppression Modalities: From Small Molecules to Nucleic Acid-Based Approaches.
Morais P, Zhang R, Yu Y Biomedicines. 2024; 12(6).
PMID: 38927491 PMC: 11201248. DOI: 10.3390/biomedicines12061284.